Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹9,360 Cr revenue.
COGS 39.8%, employees 13.3%.
“Q2 witnessed best ever custom synthesis revenue per quarter, reaching 56% of revenue mix (highest ever)”
“in the next one to two years, we will see a positive outlook...we will start seeing outcome to pipeline”
“CapEx would be higher than 2,000 crore for FY'26”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.1%▲ | 10.5% |
| ROCE | 20.1%▲ | 13.8% |
| Net Margin | 23.1%▲ | 8.7% |
| EBITDA Margin | 34.9%▲ | 16.0% |
| Debt To Equity | 0.01x▼ | 0.21x |
| Rev Growth 3yr | 2.3%▼ | 5.8% |
| EPS Growth 3yr | -9.6%▼ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹10,314 Cr +10.2% | ₹9,360 Cr +19.3% | ₹7,845 Cr +1.0% | ₹7,768 Cr -13.3% | ₹8,960 Cr +28.6% | ₹6,969 Cr +29.2% | ₹5,394 Cr +9.1% | ₹4,946 Cr |
| Other Income | ₹438 Cr +24.4% | ₹352 Cr +3.8% | ₹339 Cr -1.6% | ₹345 Cr +202.7% | ₹114 Cr +82.0% | ₹63 Cr -67.0% | ₹190 Cr +21.8% | ₹156 Cr |
| Total Income | ₹10,752 Cr +10.7% | ₹9,712 Cr +18.7% | ₹8,184 Cr +0.9% | ₹8,112 Cr -10.6% | ₹9,074 Cr +29.0% | ₹7,032 Cr +25.9% | ₹5,584 Cr +9.5% | ₹5,102 Cr |
| COGS | ₹3,955 Cr +6.2% | ₹3,725 Cr +19.0% | ₹3,129 Cr +2.5% | ₹3,054 Cr +2.9% | ₹2,967 Cr +27.7% | ₹2,324 Cr +10.2% | ₹2,109 Cr +15.5% | ₹1,825 Cr |
| ₹7,389 Cr +8.7% | ₹6,796 Cr +12.9% | ₹6,021 Cr +4.8% | ₹5,744 Cr +6.6% | ₹5,390 Cr +23.5% | ₹4,366 Cr +16.0% | ₹3,765 Cr +15.9% | ₹3,247 Cr | |
| Profit Before Tax | ₹3,289 Cr +12.8% | ₹2,916 Cr +34.8% | ₹2,163 Cr -8.7% | ₹2,369 Cr -35.7% | ₹3,684 Cr +38.2% | ₹2,666 Cr +46.5% | ₹1,819 Cr -1.9% | ₹1,855 Cr |
| Exceptional Items | (₹74 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹810 Cr +11.7% | ₹725 Cr +28.8% | ₹563 Cr +3.3% | ₹545 Cr -24.6% | ₹723 Cr +6.1% | ₹682 Cr +53.9% | ₹443 Cr -11.8% | ₹502 Cr | |
| Net Profit | ₹2,479 Cr +13.1% | ₹2,191 Cr +36.9% | ₹1,600 Cr -12.3% | ₹1,823 Cr -38.4% | ₹2,960 Cr +49.2% | ₹1,984 Cr +44.2% | ₹1,377 Cr +1.8% | ₹1,353 Cr |
| Profit (Owners) | ₹2,479 Cr +13.1% | ₹2,191 Cr +36.9% | ₹1,600 Cr -12.3% | ₹1,823 Cr -38.4% | ₹2,960 Cr +49.2% | ₹1,984 Cr +44.2% | ₹1,377 Cr +1.8% | ₹1,353 Cr |
| Other Comprehensive Income | ₹22 Cr +633.3% | ₹3 Cr | ₹0.00 Cr -100.0% | ₹12 Cr +194.1% | ₹4 Cr +915.0% | ₹0.40 Cr +14.3% | ₹0.35 Cr ↑ Recovery | (₹0.35 Cr) |
| EPS | ₹93.38 | ₹82.53 | ₹60.27 | ₹68.69 | ₹111.52 | ₹74.75 | ₹51.85 | ₹50.96 |
| Diluted Shares | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr | ₹27 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Divi's Laboratories Limited has informed the Exchange regarding 'Information regarding deduction of Income tax at source from payment of Dividend for the financial year 2025-26'.
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication - Notice to the shareholders regarding transfer of unclaimed dividend(s) and equity shares to Investor Educati...
Divi's Laboratories Limited has informed the Exchange about Transcript
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Divi's Laboratories Limited has informed the Exchange that Record date for the purpose of Dividend is 24-Jul-2026.
Divi's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2026, recommended Final Dividend of Rs. 30 per equity share.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Divi's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Divi's Laboratories Limited has informed the Exchange about Draft Order issued under Section 144C(1) of the Income Tax Act, 1961 for FY2022-23.
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Divi's Laboratories Limited has informed the Exchange about Transcript
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Divi's Laboratories Limited has informed the Exchange about Link of Recording